Abstract
With improvements in cancer treatment and supportive care, a growing population of survivors of childhood cancer at risk for significant and potentially life-threatening late effects has been identified. To provide a current snapshot of the models of care from countries with varying levels of resources and health care systems, stakeholders in childhood cancer survivorship clinical care and research were identified from 18 countries across five continents. Stakeholders responded to a survey and provided a brief narrative regarding the current state of survivorship care. Findings indicate that among pediatric-age survivors of childhood cancer (allowing for differences in age cutoffs across countries), resources are generally available, and a large proportion of survivors are seen by a physician familiar with late effects in most countries. After survivors transition to adulthood, only a minority are seen by a physician familiar with late effects. Despite the need to improve communication between pediatric oncology and primary care, only a few countries have existing national efforts to educate primary care physicians, although many more reported that educational programs are in development. These data highlight common challenges and potential solutions for the lifelong care of survivors of childhood cancer. Combining risk-based and patient-oriented solutions for this population is likely to benefit both providers and patients.
| Original language | English |
|---|---|
| Journal | Journal of Clinical Oncology |
| Volume | 36 |
| Issue number | 21 |
| Pages (from-to) | 2223-2230 |
| Number of pages | 8 |
| ISSN | 0732-183X |
| DOIs | |
| Publication status | Published - 20.07.2018 |
Funding
NOTE. Each country has a different cutoff for this age group, such as # 16 years, # 18 years, or # 21 years. Abbreviations: APP, advanced practice provider (ie, nurse practitioner or physician assistant); AU, Australia; BR, Brazil; CA, Canada; CH, Switzerland; CZ, Czech Republic; DE, Germany; DK, Denmark; FR, France; GB, Great Britain; IGHG, International Late Effects of Childhood Cancer Guideline Harmonization Group; IL, Israel; IN, India; IT, Italy; JP, Japan; NL, Netherlands; NZ, New Zealand; PCP, primary care physician; SE, Sweden; SCP, survivorship care plan; TK, Turkey; US, United States. *Starting 2 to 5 years after the end of therapy. We thank the members of the Australia and New Zealand Children’s Hematology Oncology Group Survivorship Late Effects Committee; V. Bajciova and T. Kepak of Brno, Czech Republic; H. Hasle, Professor, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark; C. Rechnitzer, DMSc, Senior Consultant, Pediatric Oncology, Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; V. Dhamankar, Assistant Director, Survivorship Programme and project PICASSO, Indian Cancer Society; M. Maeda, Department of Pediatrics, Nihon Medical University, Tokyo, Japan; L.C.M. Kremer, E. van Dulmen-den Broeder, W.J.E. Tissing, J. Loonen, M. van der Heiden, M. Louwerens, S.J.C.M.M. Neggers, H.J.H. van der Pal, A.B. Versluijs, A.C.H. de Vries, L.C. Batenburg, M.A. Grootenhuis, and J. den Hartogh, as relevant representatives of the Dutch Childhood Oncology Group–Long-Term Effects After Childhood Cancer (LATER) Board, the Netherlands; K. Yallop, Clinical nurse specialist and Late Effects Assessment Program coordinator, Starship Blood and Cancer Centre, New Zealand; and M. Jarfelt, Chairperson of the Swedish Childhood Cancer Late Effects Group, Sweden.
Research Areas and Centers
- Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)